A detailed history of Bank Of America Corp transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 44,683 shares of YMAB stock, worth $606,348. This represents 0.0% of its overall portfolio holdings.

Number of Shares
44,683
Previous 13,137 240.13%
Holding current value
$606,348
Previous $213,000 153.05%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.25 $365,933 - $544,168
31,546 Added 240.13%
44,683 $539,000
Q1 2024

May 15, 2024

SELL
$6.57 - $18.69 $153,580 - $436,897
-23,376 Reduced 64.02%
13,137 $213,000
Q4 2023

Feb 14, 2024

BUY
$4.88 - $7.42 $3,889 - $5,913
797 Added 2.23%
36,513 $249,000
Q2 2023

Aug 14, 2023

SELL
$5.68 - $10.34 $282,517 - $514,301
-49,739 Reduced 58.2%
35,716 $242,000
Q1 2023

May 12, 2023

BUY
$2.83 - $5.11 $176,399 - $318,516
62,332 Added 269.57%
85,455 $428,000
Q4 2022

Feb 10, 2023

SELL
$3.0 - $15.17 $241,389 - $1.22 Million
-80,463 Reduced 77.68%
23,123 $112,000
Q3 2022

Nov 14, 2022

BUY
$13.96 - $19.67 $484,118 - $682,135
34,679 Added 50.33%
103,586 $1.49 Million
Q2 2022

Aug 12, 2022

SELL
$8.22 - $15.13 $2.71 Million - $4.99 Million
-329,916 Reduced 82.72%
68,907 $1.04 Million
Q1 2022

May 16, 2022

BUY
$6.55 - $17.42 $2.08 Million - $5.52 Million
316,898 Added 386.81%
398,823 $4.74 Million
Q4 2021

Feb 08, 2022

BUY
$15.51 - $29.31 $25,762 - $48,683
1,661 Added 2.07%
81,925 $1.33 Million
Q3 2021

Nov 15, 2021

SELL
$27.47 - $37.31 $63,345 - $86,036
-2,306 Reduced 2.79%
80,264 $2.29 Million
Q2 2021

Sep 13, 2021

BUY
$25.45 - $37.64 $2.1 Million - $3.11 Million
82,570 New
82,570 $2.79 Million

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $593M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.